Ipilimumab - Bristol-Myers Squibb

Drug Profile

Ipilimumab - Bristol-Myers Squibb

Alternative Names: Anti CTLA-4 monoclonal antibody - Medarex; BMS-734016; MDX-010; MDX-CTLA-4; Yervoy

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Developer Aduro BioTech; AIO Studien gGmbH; Australian and New Zealand Urogenital and Prostate Cancer Group; Bavarian Nordic; Big Ten Cancer Research Consortium; Bristol-Myers Squibb; Dana-Farber Cancer Institute; European Thoracic Oncology Platform; Grupo Espanol Multidisciplinar de Melanoma; Icahn School of Medicine at Mount Sinai; Intergroupe Francophone de Cancerologie Thoracique; Ludwig Institute for Cancer Research; Massachusetts General Hospital; Medarex; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Northwestern University; Olivia Newton-John Cancer Research Institute; Ono Pharmaceutical; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University College London; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Preregistration Renal cell carcinoma
  • Phase III Gastric cancer; Glioblastoma; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Small cell lung cancer; Urogenital cancer
  • Phase II Adrenocortical carcinoma; Breast cancer; Carcinomatous meningitis; CNS cancer; Colorectal cancer; Gastrointestinal cancer; Genitourinary disorders; Gynaecological cancer; Hepatocellular carcinoma; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Pancreatic cancer; Penile cancer; Thyroid cancer; Uveal melanoma
  • Phase I/II Diffuse large B cell lymphoma; Liver cancer; Lung cancer; Solid tumours
  • No development reported HIV infections; Lymphoma

Most Recent Events

  • 15 Mar 2018 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV) (NCT03305445)
  • 15 Mar 2018 Bristol-Myers Squibb plans a phase I/II trial for Cancer (Late-stage disease, Combination therapy, Metastatic disease, Inoperable/Unresectable) in April 2018 (NCT03459222)
  • 19 Feb 2018 Phase-II clinical trials in Prostate cancer (Second-line therapy or greater, Combination therapy, Metastatic disease, Hormone refractory) in United Kingdom (Parenteral) (NCT03061539)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top